Krystal Biotech, Inc. Variable Lease, Cost
Krystal Biotech, Inc. (KRYS) reported Variable Lease, Cost of $55.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-03
- Krystal Biotech, Inc. variable lease, cost for the quarter ending 2026-06-30 was $55.00K, a 1.79% decline year-over-year.
- Krystal Biotech, Inc. variable lease, cost for the quarter ending 2026-03-31 was $63.00K, a 1.56% decline year-over-year.
- Krystal Biotech, Inc. variable lease, cost for the quarter ending 2025-12-31 was $49.00K, a 9.26% decline year-over-year.
- Krystal Biotech, Inc. variable lease, cost for the quarter ending 2025-09-30 was $58.00K, a 12.12% decline year-over-year.
- Krystal Biotech, Inc. variable lease, cost for fiscal 2025 was $226.00K, a 7.62% increase from fiscal 2024.
- Krystal Biotech, Inc. variable lease, cost for fiscal 2024 was $210.00K, a 3.45% increase from fiscal 2023.
- Krystal Biotech, Inc. variable lease, cost for fiscal 2023 was $203.00K, a 10.18% decline from fiscal 2022.
- Krystal Biotech, Inc. variable lease, cost for fiscal 2022 was $226.00K, a 41.25% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $55.00K 10-Q · filed 2026-08-03 | $118.00K 10-Q · filed 2026-08-03 | $167.00K derived: sum of 3 quarters · filed 2026-08-03 | $225.00K derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-04 | $112.00K derived: sum of 2 quarters · filed 2026-05-04 | $170.00K derived: sum of 3 quarters · filed 2026-05-04 | $226.00K derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $107.00K derived: sum of 2 quarters · filed 2026-02-17 | $163.00K derived: sum of 3 quarters · filed 2026-08-03 | $226.00K 10-K · filed 2026-02-17 | |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-03 | $114.00K derived: sum of 2 quarters · filed 2026-08-03 | $177.00K 10-Q · filed 2025-11-03 | $232.00K derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $56.00K 10-Q · filed 2026-08-03 | $119.00K 10-Q · filed 2026-08-03 | $174.00K derived: sum of 3 quarters · filed 2026-08-03 | $240.00K derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $64.00K 10-Q · filed 2026-05-04 | $118.00K derived: sum of 2 quarters · filed 2026-05-04 | $184.00K derived: sum of 3 quarters · filed 2026-05-04 | $235.00K derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $120.00K derived: sum of 2 quarters · filed 2026-02-17 | $171.00K derived: sum of 3 quarters · filed 2026-02-17 | $210.00K 10-K · filed 2026-02-17 | |
| 2024-09-30 | $66.00K 10-Q · filed 2025-11-03 | $117.00K derived: sum of 2 quarters · filed 2025-11-03 | $156.00K 10-Q · filed 2025-11-03 | $210.00K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | $51.00K 10-Q · filed 2025-08-04 | $91.00K 10-Q · filed 2025-08-04 | $144.00K derived: sum of 3 quarters · filed 2026-02-17 | $206.00K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-03-31 | $40.00K 10-Q · filed 2025-05-06 | $93.00K derived: sum of 2 quarters · filed 2026-02-17 | $155.00K derived: sum of 3 quarters · filed 2026-02-17 | $184.00K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2023-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $115.00K derived: sum of 2 quarters · filed 2026-02-17 | $144.00K derived: sum of 3 quarters · filed 2026-02-17 | $203.00K 10-K · filed 2026-02-17 | |
| 2023-09-30 | $62.00K 10-Q · filed 2024-11-04 | $91.00K derived: sum of 2 quarters · filed 2024-11-04 | $150.00K 10-Q · filed 2024-11-04 | $208.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | $29.00K 10-Q · filed 2024-08-05 | $88.00K 10-Q · filed 2024-08-05 | $146.00K derived: sum of 3 quarters · filed 2025-02-19 | $194.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | $59.00K 10-Q · filed 2024-05-06 | $117.00K derived: sum of 2 quarters · filed 2025-02-19 | $165.00K derived: sum of 3 quarters · filed 2025-02-19 | $236.00K derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $106.00K derived: sum of 2 quarters · filed 2025-02-19 | $177.00K derived: sum of 3 quarters · filed 2025-02-19 | $226.00K 10-K · filed 2025-02-19 | |
| 2022-09-30 | $48.00K 10-Q · filed 2023-11-06 | $119.00K derived: sum of 2 quarters · filed 2023-11-06 | $168.00K 10-Q · filed 2023-11-06 | $145.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $71.00K 10-Q · filed 2023-08-07 | $120.00K 10-Q · filed 2023-08-07 | $97.00K derived: sum of 3 quarters · filed 2024-02-26 | $162.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-08 | $26.00K derived: sum of 2 quarters · filed 2024-02-26 | $91.00K derived: sum of 3 quarters · filed 2024-02-26 | $172.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $42.00K derived: sum of 2 quarters · filed 2024-02-26 | $123.00K derived: sum of 3 quarters · filed 2024-02-26 | $160.00K 10-K · filed 2024-02-26 | |
| 2021-09-30 | $65.00K 10-Q · filed 2022-11-07 | $146.00K derived: sum of 2 quarters · filed 2022-11-07 | $183.00K 10-Q · filed 2022-11-07 | $152.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $81.00K 10-Q · filed 2022-08-08 | $118.00K 10-Q · filed 2022-08-08 | $87.00K derived: sum of 3 quarters · filed 2023-02-27 | $147.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-09 | $6.00K derived: sum of 2 quarters · filed 2023-02-27 | $66.00K derived: sum of 3 quarters · filed 2023-02-27 | $81.00K derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $29.00K derived: sum of 2 quarters · filed 2023-02-27 | $44.00K derived: sum of 3 quarters · filed 2023-02-27 | $57.00K 10-K · filed 2023-02-27 | $68.00K 10-K · filed 2021-03-01 |
| 2020-09-30 | $60.00K 10-Q · filed 2021-11-08 | $75.00K derived: sum of 2 quarters · filed 2021-11-08 | $88.00K 10-Q · filed 2021-11-08 | $102.00K derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | $15.00K 10-Q · filed 2021-08-09 | $28.00K 10-Q · filed 2021-08-09 | $42.00K derived: sum of 3 quarters · filed 2021-08-09 | $51.00K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $14.00K 10-Q · filed 2021-05-10 | $27.00K derived: sum of 2 quarters · filed 2021-05-10 | $36.00K derived: sum of 3 quarters · filed 2021-05-10 | $45.00K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $22.00K derived: sum of 2 quarters · filed 2021-03-01 | $31.00K derived: sum of 3 quarters · filed 2021-03-01 | $39.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $9.00K 10-Q · filed 2020-11-09 | $18.00K derived: sum of 2 quarters · filed 2020-11-09 | $26.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $9.00K 10-Q · filed 2020-08-07 | $17.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |